Compare Abeona Therapeutics Inc (ABEO) vs AT&T Inc. (T) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs AT&T Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while AT&T Inc. trades at $21.18 (market cap $146.54B). The key difference: AT&T Inc. is far larger — about 392.5× Abeona Therapeutics Inc's market cap, and AT&T Inc. pays a 5.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | T | |
|---|---|---|
Market Cap | $373.32M | $146.54B |
Sector | Health | Media |
52-Week High | $7.23 | $29.62 |
52-Week Low | $4.17 | $20.49 |
Enterprise Value | $228.22M | $291.89B |
Dividend Yield | — | 5.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AT&T (T) trades at $21.06, up 2.38% today but remains near multi-year lows amid competitive pressures. The stock shows bearish technical signals with key support at $20, while fundamentals reveal strong profitability with a 16.94% net margin and attractive valuation at a P/E of 6.93. Recent earnings beats and a 5.4% dividend yield provide support, but SpaceX competition concerns dominate sentiment.
Outlook: Undervalued with significant upside to the $29.50 consensus target, but high debt and Starlink disruption risks temper near-term optimism. Investment case hinges on execution in fiber/wireless growth against stiff competition, with cash flow stability supporting the dividend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
